Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Entera Bio Ltd (ENTX)

$1.54 -0.01 (-0.65%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	72.95M
Revenue (ttm)	40,000.00
Net Income (ttm)	-11.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-28,600.00%
Debt to Equity Ratio	0.00

Volume	612,300
Avg Vol	1,221,272
Day's Range	N/A - N/A
Shares Out	49.29M
Stochastic %K	24%
Beta	1.56
Analysts	Sell
Price Target	$9.00

Company Profile

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathy...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 2 532 7151

Website: enterabio.com

Address:

Kiryat Hadassah Minrav Building, 5th Floor, Jerusalem, Israel

rafaone Jun. 24 at 6:06 PM

$ENTX

0 · Reply

2Ben6 Jun. 24 at 6:04 PM

$ENTX so, we see the new floor here ?~ 1,50$ - we need cata. and some vol!

0 · Reply

Tata2001 Jun. 24 at 5:09 PM

$ENTX lets pushh ittt

0 · Reply

LFG2030 Jun. 24 at 3:23 PM

$ADTX $ENTX

0 · Reply

2Ben6 Jun. 24 at 2:14 PM

$ENTX lets go - big boss are in now - low rising till 3 $

0 · Reply

2Ben6 Jun. 24 at 1:22 PM

$ENTX round 3

0 · Reply

rafaone Jun. 24 at 7:12 AM

$ENTX

0 · Reply

surf_trade_and_run Jun. 24 at 1:40 AM

$ATLN on watch $ATLN $ENTX $ADTX $XCH $OTLK

0 · Reply

rob70 Jun. 23 at 11:30 PM

$ENTX Absolutely non existent volume. 97% drop from Monday. What a joke.

1 · Reply

rob70 Jun. 23 at 9:23 PM

$ENTX ZZZZZZZzzzzzzz

0 · Reply

Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market

2026-06-22T14:04:43.000Z - 2 days ago

Entera Bio gets FDA feedback on registrational protocol for EB613

Jun 22, 2026, 8:30 AM EDT - 2 days ago

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

2026-06-16T13:36:09.000Z - 8 days ago

Entera Bio and Opko Health present preclinical data for oral peptides

OPK

Jun 16, 2026, 8:33 AM EDT - 8 days ago

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

Jun 15, 2026, 8:45 AM EDT - 9 days ago

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

Jun 3, 2026, 8:00 AM EDT - 21 days ago

Entera Bio Proxy statement: Proxy filing

Jun 3, 2026, 8:00 AM EDT - 21 days ago

Entera Bio Proxy statement: Proxy filing

May 28, 2026, 8:50 AM EDT - 27 days ago

Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

May 14, 2026, 8:00 AM EDT - 5 weeks ago

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Apr 6, 2026, 1:50 PM EDT - 2 months ago

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

Apr 2, 2026, 8:45 AM EDT - 2 months ago

Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates

Mar 27, 2026, 4:05 PM EDT - 3 months ago

Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

Entera Bio announces open market purchases of stock by board members

2026-02-11T14:06:47.000Z - 4 months ago

Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation

2025-12-22T13:41:31.000Z - 6 months ago

Entera Bio announces new data on long-acting PTH tablet

Dec 22, 2025, 8:30 AM EST - 6 months ago

Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)

Entera Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 9:10 AM EST - 7 months ago

Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women

Oct 16, 2025, 8:45 AM EDT - 8 months ago

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

Entera Bio announces presentation of PK data for GLP-2 tablet treatment

2025-09-15T13:05:13.000Z - 10 months ago

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

Entera Bio Slides: Corporate Presentation

Jul 2, 2025, 2:21 PM EDT - 1 year ago

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

Entera Bio to Participate in Upcoming Events

Feb 24, 2025, 8:30 AM EST - 1 year ago

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

Aug 20, 2024, 8:00 AM EDT - 2 years ago

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

May 10, 2024, 4:10 PM EDT - 2 years ago

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Mar 26, 2024, 8:30 AM EDT - 2 years ago

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

Mar 20, 2024, 8:00 AM EDT - 2 years ago

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Mar 8, 2024, 4:05 PM EST - 2 years ago

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Nov 14, 2023, 7:30 AM EST - 2 years ago

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

Nov 14, 2023, 7:00 AM EST - 2 years ago

Entera Bio Earnings release: Q3 2023

Nov 14, 2023, 7:00 AM EST - 2 years ago

Entera Bio Quarterly report: Q3 2023

Nov 9, 2023, 2:30 PM EST - 2 years ago

Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting

Sep 12, 2023, 8:30 AM EDT - 3 years ago

Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

Sep 5, 2023, 8:00 AM EDT - 3 years ago

Entera Bio to Participate in Upcoming Investor Conferences

Aug 16, 2023, 8:30 AM EDT - 3 years ago

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Aug 15, 2023, 8:00 AM EDT - 3 years ago

0 · Reply

2Ben6 Jun. 24 at 6:04 PM

$ENTX so, we see the new floor here ?~ 1,50$ - we need cata. and some vol!

0 · Reply

Tata2001 Jun. 24 at 5:09 PM

$ENTX lets pushh ittt

0 · Reply

LFG2030 Jun. 24 at 3:23 PM

$ADTX $ENTX

0 · Reply

2Ben6 Jun. 24 at 2:14 PM

$ENTX lets go - big boss are in now - low rising till 3 $

0 · Reply

2Ben6 Jun. 24 at 1:22 PM

$ENTX round 3

0 · Reply

rafaone Jun. 24 at 7:12 AM

$ENTX

0 · Reply

surf_trade_and_run Jun. 24 at 1:40 AM

$ATLN on watch $ATLN $ENTX $ADTX $XCH $OTLK

0 · Reply

rob70 Jun. 23 at 11:30 PM

$ENTX Absolutely non existent volume. 97% drop from Monday. What a joke.

1 · Reply

rob70 Jun. 23 at 9:23 PM

$ENTX ZZZZZZZzzzzzzz

0 · Reply

Deb2021 Jun. 23 at 9:02 PM

$ENTX Yesterday

0 · Reply

LFG2030 Jun. 23 at 7:22 PM

$ENTX $ADTX $ENTX

0 · Reply

LFG2030 Jun. 23 at 6:52 PM

$ATLN $ENTX

0 · Reply

rafaone Jun. 23 at 5:52 PM

$ENTX

0 · Reply

LFG2030 Jun. 23 at 5:06 PM

$ADTX $ENTX

0 · Reply

rafaone Jun. 23 at 3:06 PM

$ENTX

1 · Reply

LFG2030 Jun. 23 at 2:59 PM

$ATLN $ENTX

0 · Reply

ZRN227 Jun. 23 at 2:23 PM

$ENTX is now a target for the institutional investors. It will cross $3 soon, after three day rule, and stay there until another positive news.

0 · Reply

LFG2030 Jun. 23 at 2:12 PM

$ENTX yes sir

0 · Reply

Jyoudoit Jun. 23 at 2:11 PM

$ENTX here we go! Get READY

1 · Reply

2Ben6 Jun. 23 at 1:59 PM

$ENTX here we go

0 · Reply

LFG2030 Jun. 23 at 1:26 PM

$ATLN $ENTX

0 · Reply

1.0.0